Business Wire

Adrian Grenier Named Chief Earth Advocate for World View

31.3.2022 18:00:00 EEST | Business Wire | Press release

Share

World View, the leading stratospheric ballooning and space tourism company, today announced environmentalist, actor, and UN Environment Goodwill Ambassador Adrian Grenier has been named its Chief Earth Advocate. In this new role he will support World View’s mission to rediscover Earth, inspiring new perspectives on the planet and encouraging deeper respect for it as a living organism. Today’s announcement follows the company’s entry into the space tourism and exploration market offering an affordable, long duration and accessible space experience on Earth.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220331005341/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Adrian Grenier, World View Chief Earth Advocate (Photo credit: Courtesy of World View)

World View designed its space tourism experience based on the company’s business purpose: World View exists to inspire, create, and explore new perspectives for a radically improved future. The company believes its space tourism experience provides customers with an “awe inspiring” journey, from the time spent at one of World View’s spaceports to the time spent at the edge of space. World View is on a mission to deliver this transformative moment to a critical mass of humans knowing that it could lead to a markedly improved future for our fragile planet.

In his new role, Grenier will collaborate with World View’s leadership to ideate and develop strategies to ensure the company's sustainability goals are met through global partnerships, programming, and initiatives. He will also contribute to the development of its environmental strategy while playing a key role in helping participants understand their individual relationship to the planet as they prepare for and reflect on their trip.

"Adrian’s history as an eco-activist speaks for itself. World View is happy to welcome Adrian as our Chief Earth Advocate. Our main goal is to enable customers to see the beauty of the Earth we inhabit so we can radically improve the future of our own planet. Adrian is an excellent advocate and will help us in our mission,” said Ryan Hartman, President and CEO of World View.

Conservation has long been at the heart of Grenier’s social activism. In 2017, he helped the UN Environment Programme launch Clean Seas, a campaign to end marine plastic pollution. He also supported Wild for Life, advocating for the conservation of sawfish. The Lonely Whale Foundation, which he co-founded, strives to inspire empathy towards marine species and develop lifelong advocates for ocean health. Its innovative StopSucking campaign aims to discourage the use of single-use plastic straws, which are particularly harmful to marine wildlife. Grenier actively supports organizations focused on habit-changing education.

“I am honored to serve as World View’s Chief Earth Advocate. The partnership allows me to use my platform to champion healthier, regenerative choices for the Earth. Space tourism is an exciting concept, and the fact that World View puts our interconnectedness squarely at the heart of exploration is in line with my personal values. Together, we will be able to honor the planet and encourage future generations to be better stewards of its resources and beauty,” said Adrian Grenier, Chief Earth Advocate of World View.

World View Mission: Rediscover Earth

World View’s global space tourism program will begin its first commercial flights in early 2024. Unlike any other space tourism company, World View plans to have flights depart from state-of-the-art spaceports located in iconic locations like the Grand Canyon and Great Barrier Reef, providing participants the opportunity to experience natural and man-made wonders from the ground and the edge of space.

Flights will lift eight participants and two World View crew members in a zero-pressure stratospheric balloon and pressurized space capsule to 100,000 feet altitude, nearly 23 miles into the stratosphere, for a life-changing experience that will last six to 12 hours with average flight duration between six and eight hours. Participants will lift off before dawn to watch the sunrise over Earth, view the curvature of our planet and experience the darkness of space. They will see a world without borders, without race and will fully experience and immerse themselves in the beauty, fragility, history, and importance of the areas surrounding each location and of the Earth itself.

ABOUT WORLD VIEW

World View is the leading stratospheric exploration company on a mission to inspire the global community to rediscover Earth. Through both its legacy Stratollite imaging and newly launched space tourism and exploration businesses, World View is working to ensure its ultimate objective: honor the planet so that future generations will feel blessed to call it home. For more information, visit worldview.space.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye